Advertisement

Opportunities for Combination Trials

  • Clive BallardEmail author
  • A. Corbett
Commentary

This paper, Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force (1) is published within the context of the long-established heterogeneity of Alzheimer’s Disease (AD) pathology, as acknowledged by the authors. It is therefore inevitable that some form of combination therapy will be required to successfully modify disease pathology and provide an effective treatment. Gautier et al outline a number of scenarios for treatment, primarily focussing on either two independent therapies targeting different aspects of a pathway involving a single pathological substrate (for example, amyloid), or two therapies targeting different substrates (for example, amyloid and tau). The paper particularly considers the scenario of combined amyloid therapies and seeks to establish the most appropriate stage of disease for optimal application of this approach. Whilst the paper offers an extremely valuable insight into this specific aspect of combination therapy we would...

References

  1. 1.
    Gauthier S, Alam J, Fillit H, et al. Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimer’s Dis in pressGoogle Scholar
  2. 2.
    Kishi T, Matsunaga S, Oya K, et al. Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis. J Alzheimers Dis. 2017;60(2):401–425. doi:  https://doi.org/10.3233/JAD-170424. Review.CrossRefGoogle Scholar
  3. 3.
    Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012 Mar 8;366(10):893–903. doi:  https://doi.org/10.1056/NEJMoa1106668.CrossRefGoogle Scholar
  4. 4.
    Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1092–1099. doi:  https://doi.org/10.1016/S1474-4422(14)70198-X. Epub 2014 Oct 5.CrossRefGoogle Scholar
  5. 5.
    Atri A, Frölich L, Ballard C, et al. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. JAMA. 2018 Jan 9;319(2):130–142. doi:  https://doi.org/10.1001/jama.2017.20373.CrossRefGoogle Scholar
  6. 6.
    Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018 Mar;17(3):213–222. doi:  https://doi.org/10.1016/S1474-4422(18)30039-5. Erratum in: Lancet Neurol. 2018 Feb 26;:.CrossRefGoogle Scholar
  7. 7.
    Spector A, Thorgrimsen L, Woods B, et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry. 2003 Sep;183:248–54.CrossRefGoogle Scholar
  8. 8.
    Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255–63. doi:  https://doi.org/10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.CrossRefGoogle Scholar
  9. 9.
    Corbett A, Owen A, Hampshire A, et al. The Effect of an Online Cognitive Training Package in Healthy Older Adults: An Online Randomized Controlled Trial. J Am Med Dir Assoc. 2015 Nov 1;16(11):990–7. doi:  https://doi.org/10.1016/j.jamda.2015.06.014.CrossRefGoogle Scholar

Copyright information

© Serdi and Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of Exeter Medical School, St Luke’s CampusUniversity of ExeterExeterUK
  2. 2.University of ExeterExeterUK

Personalised recommendations